The Department of Health – Abu Dhabi and Biocom California have announced a strategic partnership to create a formal gateway between Abu Dhabi and California’s life sciences ecosystems.
The partnership is designed to connect innovators, researchers, investors and entrepreneurs across both markets. It will support opportunities for life sciences companies to develop, validate and scale next-generation health solutions through cross-border collaboration.
This is relevant because life sciences innovation increasingly depends on regional ecosystems that can combine research, regulatory support, capital, clinical validation and market access. Abu Dhabi is positioning itself as a global life sciences hub, while California remains one of the world’s most established centres for biotechnology, pharmaceuticals and medical technology.
Biocom California represents more than 1,800 biotechnology, pharmaceutical and medical technology organisations. Through the partnership, US-based companies in its network will gain access to Abu Dhabi’s intelligent life sciences ecosystem and living lab model.
The collaboration is linked to Abu Dhabi’s Health, Endurance, Longevity and Medicine Cluster, known as the HELM Cluster. The cluster is intended to support discovery, validation and real-world implementation within one environment, offering companies a pathway to test and scale health innovations in the region.
Both parties will exchange expertise on life sciences ecosystem and cluster development, including industry best practices, policy insights and lessons learned. This is important because building a life sciences hub requires more than infrastructure; it depends on talent, regulation, market access, clinical partnerships and investor confidence.
For Abu Dhabi, the partnership strengthens its international positioning as a destination for life sciences companies seeking access to the Middle East and global markets. For Biocom California members, the agreement creates another route to international expansion, regional partnerships and real-world validation opportunities.
The development also reflects increasing competition among global cities and regions to attract life sciences investment. Countries and regional hubs are moving beyond traditional healthcare delivery and investing in research translation, digital health, biomanufacturing, longevity medicine and advanced therapeutics ecosystems.
